tbuckley/cabot-search huggingface dataset:
Reviewing the software: microcomputers and the clinician
Authors: R. Hogan
Journal: JAMA (1986)

Our first reviews of clinical software appear in this issue's BOOKS column on page 268.The Journalreceives about 2,500 books for review each year and may ultimately receive an equal number of clinical software programs as suppliers continue to proliferate. Currently, more than 250 publishers furnish us with medical and related books for review, while a recent directory of software producers contains listings of 330 vendors of medical software, about a third of whom produce clinical software specifically. We think that personal computers are additions to our libraries rather than replacements for them. In surveying<i>JAMA</i>'s most prolific book reviewers, we found that 60% of respondents are interested—indeed, extremely enthusiastic—in reviewing computer software. Since practicing medicine means acquiring and using new material, including technology, it is no surprise that physicians have shown both the aptitude and the desire to use microcomputers. Computers, as far as the individual physician
Essentials of Pathology.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Taking Time
Authors: David N. Korones
Journal: Journal of Clinical Oncology (2003)

Article Tools ART OF ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.03.070 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12947073 Taking Time David N. KoronesxDavid N. KoronesSearch for articles by this author Show More From the Golisano Children’s Hospital at Strong, University of Rochester Medical Center, Rochester, NY. https://doi.org/10.1200/JCO.2003.03.070 Full Text PDF Figures and Tables "Taking Time." Journal of Clinical Oncology, 21(17), pp. 3366–3367© 2003 by American Society of Clinical Oncology
Experimental Study of the Effect of a Series of Phosphoroorganic Pesticides (Dipterex and Imidan) on Embryogenesis
Authors: L. V. Martson, V. M. Voronina
Journal: Environmental Health Perspectives (1976)

Experiments conducted on pregnant Wistar rats show that chlorophos (Dipterex) has embroyotoxic and teratogenic effects after oral introduction in a 80 mg/kg dose during a critical period of embryogenesis. Embryotoxic and teratogenic effects are absent during the introduction of 8 mg/kg of the pesticide. The oral introduction of phthalophos (Imidan) in a 30 mg/kg dose once on day 9 of pregnancy and the introduction of a 1.5 mg/kg dose daily throughout the course of pregnancy caused increased postimplantation mortality of embryos. A dose of 30 mg/kg of phthalophos on day 9 or day 13 of pregnancy causes developmental abnormalities, including hyponathia and hydrocephaly. A 0.06 mg/kg phthalophos dose does not affect the course of embryogenesis in white rats. Thus the organophosphate pesticides Dipterex and Imidan exhibit embryotoxic and teratogenic effects at doses which significantly exceed the acutal amounts of the pesticide that can enter the human organism.
Insulin-Producing Zollinger-Ellison Tumor
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Continuing medical education. One approach
Authors: G. K. MacLeod
Journal: JAMA (1970)

For the past four years, groups of internists have voluntarily organized an annual review of internal medicine, utilizing the burgeoning Yale Medical School faculty. From an initial emphasis on preparation for board examinations, the course evolved into a comprehensive, clinically oriented review of the field, characterized by a steady enrollment growth from year to year, high attendance rates, and low cost. Continuing participant sponsorship and self-administration clearly distinguish this organizational pattern from the conventional approach to postgraduate medical education.
Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
Authors: Hang-Ping Yao, Liang Feng, Sreedhar Reddy Suthe, Ling-Hui Chen, Tian-Hao Weng, Chen-Yu Hu, Eun Sung Jun, Zhi-Gang Wu, Wei-Lin Wang, Song Cheol Kim, Xiang-Min Tong, Ming-Hai Wang
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are under intensive evaluation. Here we report the development and validation of a novel humanized anti-RON antibody-drug conjugate for cancer therapy. <h3>Methods</h3> Antibody humanization was achieved by grafting sequences of complementarity-determining regions from mouse monoclonal antibody Zt/g4 into human IgG1/κ acceptor frameworks. The selected humanized Zt/g4 subclone H1L3 was conjugated with monomethyl auristatin E using a dipeptide linker to form H-Zt/g4-MMAE. Pharmacokinetic analysis of H-Zt/g4-MMAE was determined using hydrophobic interaction chromatography and a MMAE ADC ELISA kit. Biochemical and biological assays were used for measuring RON expression, internalization, cell viability and death. Therapeutic efficacies of H-Zt/g4-MMAE were validated in vivo using three pancreatic cancer xenograft models. Toxicological activities of H-Zt/g4-MMAE were determined in mouse and cynomolgus monkey. <h3>Results</h3> H-Zt/g4-MMAE had a drug to antibody ratio of 3.77:1 and was highly stable in human plasma with a dissociation rate less than 5% within a 20 day period. H-Zt/g4-MMAE displayed a favorable pharmacokinetic profile in both mouse and cynomolgus monkey. In vitro, H-Zt/g4-MMAE induced RON internalization, which results in killing of pancreatic cancer cells with IC<sub>50</sub> values at 10–20 nM. In vivo<i>,</i> H-Zt/g4-MMAE inhibited pancreatic cancer xenograft growth with tumoristatic concentrations at 1~3 mg/kg bodyweight. Significantly, H-Zt/g4-MMAE eradicated tumors across multiple xenograft models regardless their chemoresistant and metastatic statuses. Moreover, H-Zt/g4-MMAE inhibited and eradicated xenografts mediated by pancreatic cancer stem-like cells and by primary cells from patient-derived tumors. Toxicologically, H-Zt/g4-MMAE is well tolerated in mice up to 60 mg/kg. In cynomolgus monkey, H-Zt/g4-MMAE up to 30 mg/kg had a manageable and reversible toxicity profile. <h3>Conclusions</h3> H-Zt/g4-MMAE is superior in eradication of pancreatic cancer xenografts with favorable pharmacokinetic profiles and manageable toxicological activities. These findings warrant the transition of H-Zt/g4-MMAE into clinical trials in the future.
The Nature of Human Conflicts or Emotion. Conflict and Will: An Objective Study of Disorganisation and Control of Human Behaviour.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis
Authors: B. Bernard, D. Lebrec, P. Mathurin, P. Opolon, T. Poynard
Journal: Hepatology (1997)

A meta–analysis of 12 selected randomized trials was performed to assess the efficacy of beta–blockers in the prevention of rebleeding and the effect on long–term survival in patients with cirrhosis. Five end points were assessed: rebleeding, variceal rebleeding, death, death from bleeding, and adverse events. Analyses were performed according to the intention–to–treat method. For each end point, heterogeneity and treatment efficacy were assessed by the Der Simonian and Peto methods. When a significant difference was observed, sensitivity analyses were performed by successive stratifications according to treatment duration, cause of initial bleeding, use of placebo, type of beta–blocker, type of publication, certainty of randomization, severity of cirrhosis, interval between index bleed and randomization, and methodological quality. Beta–blockers significantly increased the mean percentage of patients free of rebleeding (21% mean improvement rate, CI 95%: 10%–32%, P &lt; .001, relative risk 1.42), the mean percentage of patients free of variceal rebleeding (20% mean improvement rate, CI 95%: 11%–28%, P &lt; .001), the mean survival rate (5.4% mean improvement rate, CI 95%: 0%–11%, P = .05, relative risk 1.27), the mean percentage of patients free of bleeding death (7.4%, CI 95%: 2%–13%, P &lt; .01, relative risk 1.50). Five patients would need to be treated with beta–blockers to prevent one rebleeding episode, 14 treated to prevent one death, and 13 treated to prevent one death from bleeding. There was no significant heterogeneity among studies by both methods of analysis. In patients with esophageal varices, beta–blockers significantly increase the mean percentage of patients free of rebleeding and the mean survival rate at 2 years.
Congenital hemihypertrophy.
Authors: A W Johnston
Journal: BMJ (1973)

Many local anaesthetics are known adversely to affect in vitr tests of platelet function,3 but it is unlikely that lignocaine in the concentrations present in donor blood will have any detrimental effect.At high concentrations (10 mg/ml) lignocaine inhibits clot retrac- tion' and platelet aggregation and adhesion, but at concentrations of about 1 mg/ml no effect was seen.3The satisfactory clinical results obtained from many thousands of platelet transfusions would also support this optimism.Hypersensitivity reactions to blood in the form of urticaria have been estimated to occur in 3% of all transfusions5 and are generally attributed to the presence in the recipient's plasma of antibodies to IgA6 or IgG allotypes,7 or to the presence of reagins.8It is possible that some of these reactions are caused by prior sensitization of the re- cipient to local anaesthetics.The opportunity for sensitization of the general public is high through the widespread use of local anaes- thesia for dental, radiographic, and minor surgical pocedures as well as through blood donation and transfusion.These findings emphasize the wisdom of using some form of deplasmatized red cell preparation (such as red cell concentrates or frozen red cells) whenever the patient's requirement is only that of increased oxygen- carrying capacity.-We are, etc.,
High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)
Authors: Bruno Paiva, Norma C. Gutierrez, Laura Rosiñol, María-Belén Vidriales, María-Angeles Montalbán, Joaquín Martínez-López, Maria Victoria Mateos, María Teresa Cibeira, Lourdes Courdón, Albert Oriol, María José Terol, Maria-Asuncion Echebeste, Raquel de Paz, Felipe de Arriba, Luis Palomera, Javier De La Rubia, Joaquín Díaz-Mediavilla, Anna Sureda, Ana Gorosquieta, Adrian Alegre, Alejandro Martín, Miguel T. Hernandez, Juan José Lahuerta, Joan Blade, Jesus F. San Miguel
Journal: Blood (2011)
About the Cover . . .
Authors: Jean A. Hellman
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women
Authors: T. M. Becker
Journal: JAMA (1994)

<h3>Objective.</h3> —To assess risk factors for high-grade cervical dysplasia among southwestern Hispanic and non-Hispanic white women. <h3>Design.</h3> —Clinic-based case-control study. <h3>Setting.</h3> —University-affiliated gynecology clinics. <h3>Subjects.</h3> —Cases were Hispanic and non-Hispanic white women with biopsy-proven high-grade cervical dysplasia (n=201). Controls were Hispanic and non-Hispanic white women from the same clinics with normal cervical epithelium (n=337). <h3>Methods.</h3> —Study design included interviews focused on histories of sexually transmitted diseases, sexual behavior, reproductive histories, hygienic practices, contraceptive use, cigarette smoking, and diet. Laboratory studies included bacterial and protozoal cultures of the cervix; hybridization tests to identify human papillomavirus (HPV) genome with commercial (ViraPap and ViraType) and polymerase chain reaction—based assays; and serum antibody tests for herpes simplex virus,<i>Chlamydia trachomatis</i>, syphilis, hepatitis B, and hepatitis C. <h3>Results.</h3> —For both ethnic groups combined, after adjustment for ethnicity, age, and sexual behavior, the strongest risks for cervical dysplasia were associated with cervical HPV infection as identified by ViraPap (odds ratio [OR], 12.8; 95% confidence interval [Cl], 8.2 to 20.0) or with polymerase chain reaction (OR, 20.8; 95% Cl, 10.8 to 40.2). Other factors associated with dysplasia included cigarette smoking at the time of diagnosis (OR, 1.8; 95% Cl, 1.2 to 2.8); low income (OR, 2.2; 95% Cl, 1.2 to 4.0); low educational level (OR, 6.2; 95% Cl, 3.4 to 11.1); history of any sexually transmitted disease (OR, 1.9; 95% Cl, 1.3 to 2.7); and seroprevalence of antibodies to hepatitis B (OR, 1.8; 95% Cl, 0.9 to 3.5). For Hispanic women, HPV 16/18 identified by ViraType was strongly associated with cervical dysplasia (OR, 171.0; 95% Cl, 22.8 to 1280.5). Antibodies to herpes simplex virus type 2 were not associated with dysplasia in Hispanic women but were significantly associated with dysplasia among non-Hispanic whites. Risks associated with cigarette smoking also varied by ethnic group. <h3>Conclusions.</h3> —The strongest risk factor associated with high-grade cervical dysplasia among clinic attendees was HPV infection. Although most of the risk factors we examined showed similar associations for dysplasia for both ethnic groups, our data suggest that several different risk factors may be relevant to the development of cervical dysplasia in Hispanics compared with non-Hispanic whites who attend the same clinics. (<i>JAMA</i>. 1994;271:1181-1188)
P1.01-61 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
Authors: Y. Wu, C. Huang, Y. Fan, J. Feng, H. Pan, L. Jiang, J. Yang, X. Li, X. Liu, J. Xiong, Y. Zhao, Y. Cheng, R. Ma, J. Wang, Y. Wang, Y. Liu, D. Lin, W. Shi, X. Lin
Journal: Journal of Thoracic Oncology (2019)
A granddaughter's distress leads to lymphedema aid
Authors: M. F. Goldsmith
Journal: JAMA (1984)

Love may not always be enough. But combined with an understanding of fluid dynamics, a grandfather's love has led to the development of a device that gives young victims of a rare form of chronic lymphedema their first opportunity to live a normal life. At the recent American Academy of Dermatology meeting in Chicago, dermatologist Guinter Kahn, MD, of North Miami Beach, Fla, presented the case of an 11-year-old girl with Klippel-Trenaunay-Weber syndrome—now controlled with use of the Wright linear pump. Klippel-Trenaunay-Weber syndrome, a congenital condition of unknown cause, is characterized by hemihypertrophy of soft tissue (usually of an extremity) and, in some cases, of the skeleton as well. Patients have vascular and lymphatic overgrowth. Open lesions that can lead to osteomyelitis and eventual limb loss are common. There is no cure, and victims have been doomed to lonely and immobile lives because of both social ostracism and the difficulty
Association News.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postreperfusion biopsy as predictor of outcomes after liver transplantation
Authors: Esteban Fuentes Valenzuela, Rodrigo Najera, Javier Tejedor Tejada, Carlos Maroto Martín, Laura Sanchez Delgado, Beatriz Madrigal Rubiales, Carmen Alonso Martin, Fátima Sánchez Martín, Félix García Pajares, Carolina Almohalla Alvarez, Gloria Sánchez Antolin
Journal: Journal of Hepatology (2020)
Nonpharmaceutical Fentanyl-Related Deaths—Multiple States, April 2005–March 2007
Journal: JAMA (2008)

On April 21, 2006, increases in overdoses were reported among illicit drug users in Camden, New Jersey, via the CDC Epidemic Information Exchange (Epi-X). This alert elicited reports of similar increases in overdoses in other parts of New Jersey, and in Maryland; Chicago, Illinois; Detroit, Michigan; and Philadelphia, Pennsylvania. The increases in Chicago and Detroit had been recognized several months earlier but attributed to heroin overdoses until fentanyl was detected in the blood or urine of some decedents. Illicitly manufactured nonpharmaceutical fentanyl (NPF), a synthetic opioid 30-50 times more potent than heroin, also was found by law enforcement personnel and medical examiner staffs at the scene of some overdoses. In May 2006, to identify NPF-related deaths in six state and local jurisdictions, CDC implemented an ad hoc case-finding and surveillance system, later managed by the Drug Enforcement Administration (DEA). This report summarizes the results of that effort, which identified 1,013 NPF-related deaths that occurred during April 4, 2005-March 28, 2007. As a result, on April 23, 2007, DEA began regulating access to N-phenethyl-4-piperidone, a chemical used to make illicit NPF. Increased public health efforts are needed to improve epidemiologic data collection on drug overdoses, enable early detection of increases in drug overdoses, educate illicit drug users regarding the risks for overdose, and help users obtain treatment for their addictions.